Drug intelligence / Profile preview

ALAP-1

Development stage
Unknown
Lead developer
Radix Bioscience
Administration
Oral
01

Overview

ALAP-1 (marketed as Aller-7) is a proprietary polyherbal formulation developed for the management of seasonal allergic rhinitis. It consists of extracts from seven medicinal plants: *Phyllanthus emblica* (Amla), *Terminalia chebula* (Chebulic Myrobalan), *Terminalia bellerica* (Belleric Myrobalan), *Albizia lebbeck*, *Zingiber officinale* (Ginger), *Piper nigrum* (Black Pepper), and *Piper longum* (Long Pepper). The formulation exhibits multi-target activity, including antihistaminic, anti-inflammatory, and mast cell stabilizing properties. Specifically, it has been shown to inhibit the release of histamine from mast cells and suppress the 5-lipoxygenase (5-LOX) pathway, thereby reducing the production of leukotrienes. Clinical studies, including randomized, double-blind, placebo-controlled trials, have evaluated its efficacy in attenuating nasal symptoms and histamine-induced nasal provocation in patients with seasonal allergic rhinitis.

Brand names
Aller-7Aller7Aller 7
Other names
Aller7Aller-7Aller 7Aller-7 herbal combinationAller7 herbal combinationAller 7 herbal combination
02

Targets

ALOX5 (Arachidonate 5-lipoxygenase)

Beyond the preview

Go deeper on ALAP-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALAP-1.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call